Medifast (MED) Depreciation & Amortization (CF) (2010 - 2026)

Medifast (MED) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 6.19% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.4 million (up 13.51% YoY), and the FY2025 full-year result was $14.2 million, up 12.08% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $3.5 million, up from $3.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $4.0 million in Q2 2025 and bottomed at $2.4 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $3.3 million (2024), against an average of $3.2 million.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) surged 117.44%; it then decreased 8.94% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.0 million in 2022, then advanced by 13.51% to $3.4 million in 2023, then slipped by 5.01% to $3.2 million in 2024, then grew by 8.79% to $3.5 million in 2025, then climbed by 0.52% to $3.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.

Peer Comparison